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Abstract
Introduction
Cardiac catheterization procedures result in high radiation doses and often multiple proce-
dures are necessary for congenital heart disease patients. However, diagnostic reference
levels (DRL) remain scarce. Our first goal was finding the optimal DRL parameter and deter-
mining appropriate DRLs. The second goal was to calculate organ doses (OD), effective
doses (ED) and lifetime attributable risks (LAR) per procedure and to provide conversion
factors based on dose area product (DAP).
Materials and methods
DRLs are calculated for each procedure type, as the 75th percentile of the cumulative value
per procedure from the corresponding parameter. All irradiation events in the DICOM Struc-
tured Reports were automatically processed and simulated using PCXMC, resulting in OD,
ED and LAR. Using a Kruskal Wallis H test and subsequent pairwise comparisons, differ-
ences in median values of the DRL parameter between procedure types were assessed.
Results
Linear regression showed a strong correlation and narrow confidence interval between DAP
and product of body weight and fluoroscopy time (BWxFT), even when all procedures (diag-
nostic and interventional) are combined. Only 15% of the pairwise comparisons were statisti-
cally significant for DAP normalized to BWxFT (DAPBWxFT). The latter pairs contained less
frequent procedure types with significant outliers. For DAP normalized to BW (DAPBW), 38%
of the pairwise comparisons showed statistically significant differences. Conversion factors
from DAPBW to OD and ED were reported for various weight groups, due to the higher corre-
lation between DAPBW and both OD and ED than between DAP and both OD and ED.
Conclusions
The P75 of DAPBWxFT for all procedures combined serves as an appropriate DRL value.
This facilitates local DRL determination in smaller paediatric centres, which often have insuf-
ficient data to produce appropriate DRLs for different procedure types. Conversion factors
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are more reliable starting from DAPBW instead of DAP and should be used according to the
appropriate BW group.
Introduction
The incidence of cardiac catheterizations in patients with congenital heart disease has
increased over the last decade [1]. Due to improved technology, the procedures are becoming
increasingly complex, resulting in high radiation doses delivered to the patient [2]. Complex
therapies often need multiple interventions, thus increasing the cumulative dose to the patient
[3]. Improved care significantly increased the life expectancy of the patients, increasing the
time for stochastic radiation effects to develop. In addition, children are generally at higher
lifetime radiation risk than adults and since they are smaller a larger fraction of their body is
exposed to the direct X-ray beam [4–6].
Data on diagnostic reference levels (DRLs) of cardiac catheterization in congenital heart
disease patients remain scarce. DRLs are simple threshold levels of easily measurable and avail-
able dose quantities, e.g. DAP in interventional cardiology, to identify examinations with
unusually high patient doses [7]. Comparison of a department’s median exposure level to the
DRL, can assist in identifying examinations with unusually high patient doses [8]. DRLs are
therefore a valuable tool in optimizing and controlling radiation exposure to the patient. The
PiDRL project by the European Society of Radiology (ESR), delivered European guidelines on
DRLs for paediatric imaging in 2016. Recently these guidelines were published as RP 185 in
the radiation protection series of the European Commission. In current study, the latter guide-
lines were applied to generate local DRLs.
Estimation of radiation risk to the population in cardiac catheterizations is most often done
in literature by reporting effective dose. The organ and effective doses found in current litera-
ture are estimated by applying conversion factors from dose area product (DAP) values
reported by the X-ray modality. Either a single conversion factor is applied to the cumulative
DAP of a whole catheterization procedure, or several conversion factors are applied by per-
forming Monte Carlo simulations or thermoluminescent dosimeter (TLD) measurements
with anthropomorphic phantoms for a limited number of irradiation events per procedure
and a limited variation in exposure parameters [6, 9–14]. In present study we calculated organ
and effective doses by performing Monte Carlo simulations of all irradiation events (fluoros-
copy and cinegraphy exposures) per procedure. We evaluated if the use of single conversion
factors to calculate ED from DAP values (CFED) is feasible.
Based on the simulated individual doses, lifetime attributable radiation risk (LAR) were cal-
culated for each catheterization using the BEIR VII risk models. We determined appropriate
organ dose conversion factors from DAP values from which the corresponding LAR can be
calculated [5].
To our knowledge this is the first study taking into account all irradiation events and
patient ages and sizes to automatically determine organ and effective doses and radiation risk
and additionally to provide DAP to organ dose conversion factors (CFOD) appropriate for sub-
sequent LAR determination.
Methods and materials
Imaging modality and data acquisition
All procedures were performed on a biplane Philips AlluraClarity FD20/10 cath lab (Philips
Healthcare, Best, The Netherlands). The modality sends DICOM Radiation Dose Structured
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Reports (RDSR) at the end of each procedure to GE DoseWatch, a dose management software
(GE Healthcare, Milwaukee, WI, USA). In DoseWatch, the exposure parameters (tube voltage
and current, pulse width, number of pulses, additional filtration, DAP, air kerma, etc.), patient
parameters (length, weight, sex, age) and geometric information (C-arm projection and angu-
lation, source to image detector distance, table position, etc.) of any irradiation event and each
procedure are easily accessible.
Catheterization procedures
Data were anonymized and retrospectively obtained from 242 consecutive cardiac catheteriza-
tions performed in the paediatric interventional cardiology department at Ghent University
Hospital. This study was approved by the Ethics Comittee of Ghent University Hospital
(approval number 2016–1584). No written or oral consent was obtained from the patients
since this was a retrospective study for which data were anonymized. The catheterizations
were performed between January 2015 and September 2017. Procedures involving rotational
angiography were excluded from the study since the RDSR did not contain sufficient informa-
tion of these irradiation events to be able to perform Monte Carlo simulations. In the end, data
of 222 procedures are remaining. Additional filtration of 1mm aluminum and 0.4mm copper
was inserted for all exposures and anti-scatter grid was never removed. Procedures are
grouped into diagnostic and interventional procedures. The latter are subdivided further into
different procedure types, as recommended by RP 185 [7].
Diagnostic reference levels
The European guidelines provide recommendations on how to establish and use DRLs for pae-
diatric x-ray examinations and procedures. They recommend the use of air kerma-area prod-
uct (here referred to as DAP) as the primary DRL quantity for interventional cardiology
procedures. The 75th percentile (P75) of the DAP distribution should be calculated for several
recommended patient weight groups since paediatric patients (premature babies until obese
adolescents) may vary in size by a factor of 200. They also suggest DAP normalized to body
weight (DAPBW) as a useful parameter. In case DAP and body weight have a clear linear corre-
lation, DAPBW can be used as a single DRL parameter instead of determining different DRLs
per weight group. Additionally, the product of body weight and fluoroscopy time (BWxFT) is
briefly mentioned as a potentially useful parameter [7].
This study provides the 75th percentile of DAPBW distribution as a primary DRL parameter,
for different procedure types. The usefulness of DAP normalized by BWxFT as the primary
DRL parameter is assessed. The correlation between DAP and body weight on the one hand
and between DAP and the product of fluoroscopy time and patient weight on the other hand,
are investigated. Likewise, the 75th percentile of the air kerma at interventional reference
point, fluoroscopy time and number of cinegraphic frames are serving as additional DRL
quantities as recommended. These data are retrospectively available in DoseWatch.
Organ and effective doses
Organ and effective doses are calculated using PCXMC, a Monte Carlo simulations software
using mathematical phantoms [15]. The Monte Carlo method simulates photon transport
through the phantom according to the stochastic nature of the different physical interaction
processes between photons and matter. For each interaction the energy deposition and there-
fore dose is calculated taking into account the tissue characteristics of the organ the photon
interacted with. The 222 procedures included in this study account for 14,013 irradation
events. Each of these exposures are simulated using PCXMC. Due to the vast amount of
Cardiac catheterization of CHD patients: DRLs and risks
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irradiation events, the simulations were automated using in-house developed scripts and a cus-
tomized database. Fig 1 gives a schematic overview of this process. First, RDSR data at the end
of each examination are forwarded from DoseWatch to a customized database. Second, this
database is then queried for the irradiation event data of the procedure. Third, a mathematical
phantom is selected based on patient age and is adjusted to the patient’s height and weight.
Assuming that the heart of the patient is positioned at the isocenter of the C-arms, the focal
spot to entrance skin point distance (FSD) can be calculated from the previously determined
phantom specifications and C-arm position. Fourth, the FSD and the rest of the irradiation
event data are filled into the Autocalc definition file. Fifth, as soon as PCXMC is executed, the
Autocalc definition file will be simulated. Sixth, lifetime attributable risks (LARs) are calculated
from the organ doses and are finally stored together with the organ and effective doses into the
database. The process is repeated for each irradiation event.
Conversion factors for organ doses (CFOD) and effective dose (CFED) from DAP will be cal-
culated based on the results obtained by the process described above. Conversion factors are
divided into the weight categories recommended by the PiDRL project.
Risk estimation
Lifetime attributable risk (LAR) of cancer incidence and mortality are determined according
to the BEIR VII Phase 2 risk models. Risk models are available for several types of cancers and
take into account the age- and gender-dependent incidence and mortality rates within the
Fig 1. Automated risk assessment dataflow. 1: DICOM RDSR data are stored in Database. 2: Database is queried for irradiation events. 3: Phantom specifications
are determined by patient age, height and weight. 4: FSD is calculated and stored with other data of the queried irradiation event into a definition file. 5: Definition
file is simulated by executing PCXMC. 6: Results are stored back into the database.
https://doi.org/10.1371/journal.pone.0220359.g001
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Euro-American population. The LAR factors of tables 12D-1 and 12D-2 of the BEIR VII Phase
2 report are adjusted to a dose and dose rate effectiveness factor (DDREF) of 2, as recom-
mended by the ICRP [16].
DAP to LAR per 100,000 incidences or deaths conversion can be estimated by first applying
the aforementioned DAP to organ dose conversion factors and subsequently using tables 12D-
1 and 12D-2 of the BEIR VII Phase 2 report.
Statistical analysis
For significance testing of DAP and normalized DAP differences between procedure groups, a
Kruskal Wallis H test was performed. Subsequently, pairwise comparisons were performed
using Dunn’s procedure with a Bonferroni correction for multiple comparisons.
Correlation between DAP and body weight and DAP and the product of body weight and
fluoroscopy time was assessed via linear regression. Conversion factors from DAP to organ
and effective dose, are determined as the slope coefficient of a linear regression analysis.
All statistical analyses were performed using IBM SPSS Statistics 25 (IBM corp, USA).
Results
Diagnostic reference levels
Taking into account all procedures, the DAP and DAPBW values range from 16 to 17844 cGy.
cm2 and from 0.3 to 254.9 cGy.cm2/kg respectively. Fluoroscopy times are between 0.5 and
100.4 minutes and the number of cinegraphic frames varied from 0 to 2162 frames. Addition-
ally the air kerma, measured at the interventional reference point, is between 0.4 and 1454.7
mGy. Median contribution of fluoroscopy to total DAP for all interventional procedures is
91%, compared to 77% for diagnostic procedures. The latter difference was statistically signifi-
cant. Furthermore, the biplane configuration is applied in 73% of interventional procedures
and 85% of the diagnostic procedures. Table 1 provides the data in more detail, for different
types of catheterization procedures, as median (P25-P75) values with P25 and P75 the 25th and
75th percentile respectively. The primary DRL values (75th percentiles) are given in Table 2, for
the two potential DRL parameters, i.e. DAPBW and DAPBWxFT.
For both parameters DAPBW and DAPBWxFT, differences between procedure types were sta-
tistically significant (p<0.0005). Considering DAPBW, pairwise comparison showed a statisti-
cally significant difference for 15 out of 36 possible pairs. For DAPBWxFT, only six pairs
showed a statistically significant difference.
Linear regression between DAP and body weight results in an R2 value of 0.39 for all proce-
dures combined. Table 3 documents median (P25-P75) values of DAP in each weight category
suggested by RP 185 and one additional weight category larger than or equal to 80 kg. The R2
values for the separate procedure types range from 0.35 to 0.88. Linear regression analysis
between DAP and the product of body weight and fluoroscopy time yields an R2 of 0.86 for all
categories combined. When grouping the procedures in various procedure types, R2 values
ranged from 0.73 to 0.98.
Organ and effective doses
Only the organ doses relevant to calculate lifetime risk are taken into account in this study,
including the heart dose. Apart from the heart, the highest organ doses relevant for LAR calcu-
lation, i.e. for liver, lungs, breasts, remainder tissue and active bone marrow are provided as
median (P25-P75) values in Table 4.
Cardiac catheterization of CHD patients: DRLs and risks
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The effective doses are calculated using the tissue weighting factors of ICRP publication 103
(ED103) and are tabulated in Table 1 for several procedure types. ED103 ranges from 0.05 to
61.68 mSv with an average value of 5.1 mSv.
A strong correlation between DAP and ED103 (CFED) is noticed (R
2 = 0.85), which is
improved when the data is grouped into the weight groups recommended by the RP 185
Table 1. Radiation exposure parameters per procedure type.
DAP Air kerma Fluoroscopy time Number of cinegraphic frames Effective dose
(ICRP103)
[cGy.cm2] [mGy] [s] [–] [mSv]
All (n = 222) 193.67
(68.48–709.93)
27.05
(11.52–92.27)
477.50
(281–1088)
253
(96–578)
1.83
(0.91–5.36)
Diagnostic (n = 33) 200.31
(58.38–1187.179)
26.43
(11.21–114.73)
481
(267–1110)
456
(319–908)
3.34
(1.32–6.5)
Interventional (n = 189) 189.29
(68.93–694.81)
27.17
(12.20–90.60)
476
(296–1068)
226
(17–532)
1.60
(0.90–5.20)
ASD closure (n = 33) 135.2
(71.67–325.19)
13.88
(7.94–27.5)
254
(185–436)
0
(0–11)
0.78
(0.55–1.66)
PFO closure (n = 17) 355.35
(234.11–450.04)
26.93
(14.04–34.55)
243
(168–276)
0
(0–10)
0.9
(0.53–1.04)
PDA closure (n = 18) 87.35
(49.83–117.09)
15.03
(10.02–21.41)
358.50
(275–419)
172
(132–233)
1.22
(0.95–1.58)
Single Balloon Valvuloplasty (n = 43) 92.6
(45.17–226.38)
15.45
(10.47–39.33)
490
(408–851.50)
216
(125–294)
1.49
(0.92–3.14)
Single Balloon Angioplasty (n = 34) 118.75
(51.22–414.31)
23.25
(12.35–84.44)
486.50
(311–964)
324
(234–598)
2.06
(1.19–6.06)
Multi Balloon Dilatation (n = 13) 736.19
(254.53–1255.07)
75.91
(48.17–210.24)
1142
(729–1584)
452
(308–890)
4.03
(3.2–8.84)
Pulmonary Valve Replacement (n = 7) 9335.03
(7664.79–12212.58)
923.93
(776.39–1008.7)
2055
(1745–3566)
1274
(1210.5–1797.5)
32.84
(30.94–36.29)
Stenting (n = 14) 1957.23
(694.81–3906.06)
176.18
(102.85–434.30)
1642
(977–1870)
1052
(719–1356)
10.59
(6.84–12.38)
Cumulative procedure parameter values indicated by the X-ray modality and the resulting effective dose. Values are presented as median (P25-P75); ASD: atrial septal
defect; PDA: patent ductus arteriosus; PFO: patent foramen ovale.
https://doi.org/10.1371/journal.pone.0220359.t001
Table 2. DRL parameters per procedure type.
DAPBW
[cGy.cm2.kg-1]
DAPBW x FT
[cGy.cm2.kg-1.min-1]
All (n = 222) 30.30 1.99
Diagnostic (n = 33) 33.54 3.59
Interventional (n = 189) 29.94 1.74
ASD closure (n = 33) 10.72 1.48
PFO closure (n = 17) 5.69 1.45
PDA closure (n = 18) 9.01 1.33
Single Balloon Valvuloplasty (n = 43) 19.21 1.53
Single Balloon Angioplasty (n = 34) 41.99 2.01
Multi Balloon Dilatation (n = 13) 55.99 1.91
Pulmonary Valve Replacement (n = 7) 153.32 3.50
Stenting (n = 14) 71.89 3.21
Primary DRL parameters. 75th percentiles of the distribution per procedure group are given; ASD: atrial septal defect;
PDA: patent ductus arteriosus; PFO: patent foramen ovale.
https://doi.org/10.1371/journal.pone.0220359.t002
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(R2 from 0.95 to 0.97). The correlation is even better when considering DAPBW instead of
DAP for each weight group (R2 from 0.96 to 0.99). Conversion factors are also calculated for
the frontal and lateral C-arm separately. The results of linear regression analysis between
DAPBW and ED103, i.e. the slope coefficients and limits of the 95% confidence intervals, are
shown in Table 5. All linear regressions are statistically significant. Since the X-ray modality is
a biplane modality and DICOM RDSR communicates cumulative DAP values for the whole
procedure for each C-arm, we also provide separate conversion factors for the frontal and lat-
eral C-arm. The sum of the effective doses calculated for both C-arms using their correspond-
ing CFED, yields the cumulative effective dose of the procedure. The lateral C-arm in current
study almost exclusively acquires lateral projections (on average LAO87˚-CRA1˚). Hence,
when lateral acquisitions are not employed on a monoplane system or during a monoplane
Table 3. DAP per weight category.
DAP [Gy.cm2] Weight category [kg]
< 5 5 −< 15 15 −< 30 30 −< 50 50 −< 80 � 80
n 25 72 43 18 52 12
Median 0.62 0.73 1.87 7.12 8.68 31.84
P25 0.38 0.41 0.82 2.77 3.79 5.12
P75 1.15 1.35 4.40 24.74 37.14 75.25
DAP per weight category, for all procedure types combined.
https://doi.org/10.1371/journal.pone.0220359.t003
Table 4. Organ doses per procedure type.
Heart Liver Lungs Breasts Remainder Active bone marrow
[mGy] [mGy] [mGy] [mGy] [mGy] [mGy]
All 5.26
(2.86–17.56)
1.36
(0.6–4.37)
5.84
(2.91–19.52)
3.31
(1.31–8.88)
1.28
(0.67–4.13)
1.24
(0.5–3.56)
Diagnostic 8.57
(3.37–21.97)
2.89
(0.79–5.85)
11.2
(4.11–23.49)
6.01
(2.93–11.13)
2.3
(0.87–4.68)
1.48
(0.59–4.28)
Interventional 4.94
(2.82–16.55)
1.17
(0.59–4.21)
5.32
(2.91–18.54)
2.94
(1.28–8.38)
1.12
(0.66–3.55)
1.17
(0.5–3.35)
ASD closure 2.40
(1.33–4.03)
0.56
(0.33–1.22)
2.75
(1.85–5.01)
1.05
(0.68–2.19)
0.7
(0.37–1.4)
0.57
(0.35–1.45)
PFO closure 2.95
(1.69–3.74)
0.57
(0.26–0.66)
3.01
(1.97–3.43)
0.6
(0.36–0.78)
0.8
(0.39–0.88)
1.27
(0.79–1.54)
PDA closure 3.75
(3.13–5.32)
0.83
(0.59–1.04)
4.02
(2.89–5.86)
3.08
(1.84–4.34)
0.77
(0.62–1.02)
0.5
(0.39–0.62)
Single Balloon Valvuloplasty 4.65
(3.03–9.86)
0.99
(0.7–2.35)
4.98
(3.09–9.35)
2.67
(1.84–5.8)
1.01
(0.63–2.15)
0.8
(0.42–1.88)
Single Balloon Angioplasty 6.23
(3.66–18.53)
1.64
(0.72–5.15)
5.84
(3.92–21.73)
3.91
(1.77–7)
1.39
(0.78–4.36)
0.79
(0.42–3.35)
Multi Balloon Dilatation 13.46
(8.9–34.46)
3.33
(2.51–8.08)
15.47
(11.04–43.72)
3.93
(2.66–14.07)
2.57
(2.08–7.99)
3.43
(2.36–6.96)
Pulmonary Valve Replacement 110.17
(106.98–123.98)
26.61
(24.5–34.06)
114.87
(109.13–136.37)
64.5
(31.47–66.27)
22.59
(18.54–28.54)
26.89
(22.24–39.02)
Stenting 29.84 (22–47.16) 7.37
(6.05–11.65)
39.24
(24.32–53.72)
11.83
(8.28–16.87)
7.11
(4.34–11.16)
7.77
(4.02–9.72)
Heart dose and the top five organ doses to organs accounting for LAR determination; ASD: atrial septal defect; PDA: patent ductus arteriosus; PFO: patent foramen
ovale.
https://doi.org/10.1371/journal.pone.0220359.t004
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procedure, the Frontal CFED from Table 5 can also be used as a single conversion factor to cal-
culate ED from DAP. When the system only reports one cumulative DAP value per procedure
and lateral acquisitions are applied, we suggest to use the Total CFED.
Likewise conversion factors from DAPBW to OD are reported instead of DAP to OD, since
the correlations were better and 95% confidence intervals were smaller, when normalizing
DAP by patient weight. The conversion factors are tabulated in Table 6.
Risk estimation
Lifetime attributable risk is calculated according to the BEIR VII Phase 2 risk models. The
results are tabulated in Table 7 for all cancers combined as median(P25-P75) values per
100,000 incidences or deaths. Including all procedures, the median lifetime risk for cancer
incidence and mortality are respectively equal to 0.034% and 0.021% with respective ranges
from 0.001% to 0.315% and from 0.001% to 0.146%.
Using the conversion factors in Table 6, one can calculate the organ dose from normalized
DAP values and subsequently determine the corresponding LAR using tables 12D-1 and 12D-
2 of the BEIR VII Phase 2 report. As a practical example for this workflow, LAR for lung cancer
incidence is calculated here from DAP by the given conversion factors: For a 10-year-old male
patient weighing 35 kg, a DAP equal to 683.13 cGy.cm2 was noted, i.e. a DAPBW equal to
683.13 / 35 = 19.52 cGy.cm2.kg-1. From Table 4 we get a combined biplane conversion factor
to lung dose equal to 77.117 mGy.Gy-1.cm-2.kg. Multiplying this factor with the DAPBW previ-
ously determined, gives us a lung dose of 77.117×19.52/100 = 15.05 mGy. More accurate organ
dose estimates will be obtained when applying the frontal and lateral C-arm conversion factors
separately on their respective DAP contribution and then adding both results to get the total
organ dose. Table 12D-1 of the BEIR VII Phase 2 report shows the estimated lifetime risk of
being diagnosed with lung cancer for a male exposed to 0.1 Gy at age 10 as 216 per 100,000,
which is adjusted by a DDREF of 1.5. Our example patient received 15.05 mGy of dose to the
lungs, which results in an estimate of 0.01505/0.1×216 = 33 per 100,000. When adjusting for a
DDREF of 2, instead of the tabulated 1.5, we obtain an estimate of 33×1.5/2 = 25 per 100,000.
Table 5. CFED per weight category.
CFED
[mSv.Gy-1.cm-2.kg]
Weight category [kg]
< 5 5 −< 15 15 −< 30 30 −< 50 50 −< 80 � 80 All
Total n 25 72 43 18 52 12 222
Slope 14.17 14.07 19.79 20.63 20.89 25.59 19.84
LL 13.50 13.48 18.60 19.38 19.67 23.35 19.17
UL 14.84 14.66 20.98 21.88 22.10 27.83 20.51
Frontal n 25 72 43 18 52 12 222
Slope 11.37 11.52 15.32 16.71 16.17 19.42 15.62
LL 11.04 11.09 14.87 15.99 15.31 18.09 15.17
UL 11.69 12.96 15.76 17.43 17.03 20.76 16.07
Lateral n 25 64 28 14 26 8 165
Slope 18.29 18.65 25.22 26.28 31.58 35.97 27.81
LL 17.63 17.73 23.61 23.70 30.12 33.47 26.74
UL 18.96 19.57 26.82 28.87 33.03 38.46 28.89
Results of the linear regression analysis between ED and DAPBW. The slope coefficients, i.e. the conversion factors, are shown in bold. Total CFED is used when one
cumulative DAP value is available per procedure, Frontal and Lateral CFED are used for each C-arm separately on a biplane system; LL: lower limit of the 95%
confidence interval; UL: upper limit of the 95% confidence interval; n: number of values included in the analysis.
https://doi.org/10.1371/journal.pone.0220359.t005
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Discussion
Diagnostic reference levels
Median DAP values are amongst the lowest values found in literature for patient weight lower
than 30 kg. However, 75th percentile values are in the higher range of values compared to
Table 6. CFOD per weight category.
CFOD
[mGy.Gy-1.cm-2.kg]
Weight category [kg]
< 5 5 −< 15 15 −< 30 30 −< 50 50 −< 80 � 80 All
Heart Biplane 37.38 37.73 68.87 63.08 65.17 91.26 62.07
Frontal 26.17 24.76 41.88 32.14 44.28 68.01 41.73
Lateral 54.48 60.78 99.92 131.00 110.94 127.90 101.91
Stomach Biplane 7.09 7.93 10.68 9.76 8.42 11.11 8.77
Frontal 6.29 7.81 9.26 10.98 8.65 12.31 8.99
Lateral 7.98 7.91 12.77 7.76 7.14 8.78 8.12
Colon Biplane 1.10 1.06 0.87 0.68 0.50 0.77 0.68
Frontal 0.90 0.88 0.76 0.61 0.40 0.54 0.53
Lateral 1.40 1.39 1.04 0.77 0.72 1.14 0.97
Liver Biplane 11.93 12.77 14.92 19.90 18.29 23.16 17.57
Frontal 7.65 8.54 10.33 15.65 12.36 11.00 11.71
Lateral 17.72 21.01 20.96 24.60 32.01 42.32 28.53
Lungs Biplane 41.73 45.20 76.48 77.12 75.93 95.01 71.34
Frontal 36.99 39.47 53.92 61.82 56.02 60.19 53.66
Lateral 49.10 54.99 103.51 109.44 120.27 148.40 104.98
Urinary Bladder Biplane 0.31 0.23 0.11 0.06 0.03 0.06 0.09
Frontal 0.26 0.19 0.10 0.05 0.02 0.03 0.06
Lateral 0.39 0.32 0.14 0.08 0.05 0.09 0.14
Thyroid Biplane 3.57 3.33 3.02 2.17 1.69 2.40 2.24
Frontal 2.72 2.69 2.10 2.17 1.35 1.60 1.72
Lateral 4.77 4.68 4.29 2.36 2.39 3.77 3.29
Active Bone Marrow Biplane 5.56 6.45 9.92 13.94 21.25 26.37 17.37
Frontal 6.47 7.36 9.49 16.43 23.13 30.76 19.76
Lateral 4.31 4.66 10.92 8.92 15.16 19.15 12.03
Breasts Biplane 34.72 27.65 27.33 31.92 27.13 27.25 28.23
Frontal 21.37 15.40 22.73 13.39 9.86 9.80 11.98
Lateral 54.60 50.87 31.47 51.05 72.57 62.56 60.24
Oesophagus Biplane 32.94 31.23 45.22 40.50 30.97 62.48 31.83
Frontal 26.71 27.24 37.38 38.10 30.22 67.03 30.53
Lateral 42.25 38.09 62.84 35.27 43.47 55.44 44.92
Ovaries Biplane 0.67 0.56 0.34 0.19 0.12 0.21 0.25
Frontal 0.56 0.46 0.29 0.17 0.08 0.12 0.18
Lateral 0.85 0.74 0.42 0.24 0.20 0.36 0.38
Remainder Male Biplane 9.32 10.53 14.36 15.31 14.50 19.51 14.17
Frontal 7.94 9.57 11.94 14.31 12.78 17.58 12.65
Lateral 11.10 11.83 17.50 18.21 18.10 22.45 17.05
Remainder Female Biplane 9.34 10.54 14.37 15.32 14.50 19.52 14.18
Frontal 7.95 9.58 11.95 14.32 12.79 17.59 12.66
Lateral 11.12 11.85 17.51 18.22 18.10 22.46 17.06
Results of the linear regression analysis between OD and DAPBW
https://doi.org/10.1371/journal.pone.0220359.t006
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literature. This is due to the relatively low number of procedures in this study, the high differ-
ences in procedure complexity and the higher variability noticed for current study in the high-
est weight category.
Onnasch et al., Chida et al. and Ubeda et al. all found reasonable correlations between DAP
and body weight [10, 11, 17]. Ubeda et al. reported R2 values between 0.247 and 0.698 for dif-
ferent types of procedures, which is confirmed in the current study with values between 0.354
and 0.883 [11]. Therefore DAPBW is suggested here as a primary DRL parameter for different
procedure types, with respective median (P25-P75) values of 0.163 (0.088–0.324) and 0.096
(0.051–0.294) Gy.cm2/kg for diagnostic and interventional procedures. These DRLs, as wel as
the median values, are lower than the ones reported by Onnasch et al., i.e. 0.409 and 0.559 Gy.
cm2/kg for diagnostic and therapeutic procedures respectively [17]. The DRLs are higher than
the ones reported by Ubeda et al, i.e. 0.163 and 0.170 Gy.cm2/kg for diagnostic and therapeutic
procedures respectively, although the median values of both studies are matching quite well
[11].
In contrast to literature, current study recorded higher median DAP for diagnostic than for
interventional procedures. This can be attributed to the extensive use of transesophageal ultra-
sound, during ASD, PFO and VSD procedures in our department. Hence, total DAP of these
procedures is almost entirely attributed to fluoroscopy, resulting in low DAP values. ASD,
PFO and VSD procedures account for 29% of all interventional procedures. Furthermore,
biplane configuration was used more frequently in diagnostic procedures. Additionally, the
number of frames is almost doubled in diagnostic procedures compared to interventional pro-
cedures, while fluoroscopy time was equal in both groups, as shown in Table 1. Thus, cinegra-
phy is more frequently used in diagnostic examinations. This is as expected since during
diagnostic examinations the cardiologists want to have a good understanding of the morphol-
ogy and pressure values of a larger anatomic region, while for interventional procedures they
focus on a specific feature or malformation (e.g. stenosis of the pulmonary artery or valve, aor-
tic coarctation, . . .) of the anatomic area.
RP 185 states that DRLs should be based on statistically relevant numbers of patient dose
data. They recommend to use at least 20 cases per procedure type and per patient group for
complex procedures such as fluoroscopically guided procedures. Yet, Table 1 shows several
procedure types with less than 20 cases, after 21 months of data collection. The DRLs from the
latter procedure types should therefore be consulted with care since they might be less mean-
ingful. However, smaller departments inherently deal with too few data. Hence with DAPBW,
it will probably not always be possible to set DRL values, or to gather sufficient data to compare
with existing DRLs, for all procedure types in smaller departments within a reasonable time
frame.
With the nine different procedure types in this study, 36 pairwise procedure type compari-
sons can be made. As suggested by the European guidelines, separate local DRLs were pro-
posed for each procedure type. This suggestion is validated in this study for DAPBW, since 15
out of 36 (i.e. 42%) possible pairwise procedure comparisons, subsequent to the Kruskal Wallis
Table 7. Incidence and mortality LAR values.
LAR Male Female
[per 100,000] Incidence Mortality Incidence Mortality
All procedures (n = 116) (n = 106)
All cancers 23 (11–57) 17 (8–43) 55 (25–129) 30 (15–90)
Median (P25-P75) LAR (BEIR) values per 100,000 incidences or deaths
https://doi.org/10.1371/journal.pone.0220359.t007
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H test, were statistically significant. By splitting the procedures into different procedure types,
one thus takes into account inter-procedure type differences in complexity. However, intra-
procedure type differences are not considered in this way. When normalizing DAP by the
product of body weight and fluoroscopy time, i.e. DAPBWxFT, only 6 out of 36 pairwise proce-
dure comparisons showed a statistically significant difference. Additionally, in each of the
latter six comparisons, one of the procedure pairs were either stenting or pulmonary valve
replacement procedures, which both had significant outliers and which were procedures
with respectively the lowest and third lowest number of cases. Hence we can hypothesize that
DAPBWxFT inherently takes into account inter-procedure type differences.
A strong linear correlation (R2 = 0.88) between DAP and the product of body weight and
fluoroscopy time for all procedures combined was observed. Taylor et al. determined optimal
sample sizes to calculate DRL values for CT, based on the 95% confidence interval in percent-
age of their median (CI95/med) being below 10% [18]. Considering all procedures, CI95/med
values in current study were 63.5, 51.2 and 16.7% for DAP, DAPBW and DAPBWxFT respec-
tively. This trend remains when considering the procedure types separately. Thus, applying
DAPBWxFT also seems to account for intra-procedure complexity differences and yields nar-
rower confidence intervals even when all procedures are pooled into one group.
Chida et al. and Nguyen et al. also observed better correlation between DAP and BWxFT,
than between DAP and body weight only [10, 19]. Sullivan et al. reported data of procedures
performed on the same biplane X-ray modality as in this study. They observed an average
(95% CI) DAPBWxFT of 2.18 (2.02–2.34) cGy.cm
2.kg-1.min-1, agreeing closely with our value of
1.80 (1.65–1.96) cGy.cm2.kg-1.min-1 [20].
These findings suggest that, when considering DAPBWxFT as the primary DRL parameter,
only one DRL value for all procedures combined is feasible. This is highly favorable for the
many smaller paediatric catheterization departments with insufficient data to calculate DRL
values per procedure type and body weight group in a reasonable time span, since the latter
parameter seems to take into account both intra- and inter-procedure type differences. When-
ever a high patient dose is reached, comparison to the DRL may help in finding the cause of
said high exposure. For example, if a procedure’s DAPBWxFT exceeds the DRL, several reasons
may apply. Maybe the cinegraphy contribution was higher than usual, due to an increased
number of acquisitions, or a high dose cinegraphy protocol was used. Selecting a wrong fluo-
roscopy protocol, with low filtration and therefore higher dose, could be the cause. For small
patients, anti-scatter grid may be inserted, causing higher exposure than usual. This shows that
secondary DRL parameters, like fluoroscopy time and number of frames, can assist the pri-
mary DRL in this root analysis. Most dose management systems currently available provide
alerting and reporting tools. At the end of the procedure, data are sent to the dose management
software, which will compare data of the current study to the DRL and/or to statistics calcu-
lated from the previous procedures. If the dose of the current procedure exceeds the aforemen-
tioned values, the health professional can be notified by an alert popping up in a worklist, or
by e-mail. Additionally, these systems can send monthly reports, showing a list of the proce-
dures where the doses were unusually high.
Effective doses, organ doses and risk estimation
Effective dose in current study ranges from 0.05 to 61.68 mSv with respective median
(P25-P75) values of 3.34 (1.32–6.5) and 1.58 (0.86–4.74) mSv for diagnostic and interventional
procedures. Bacher et al. calculated effective dose using detailed Monte Carlo simulations [6].
They calculated a median effective dose equal to 4.6 and 6.0 mSv for diagnostic and therapeutic
catheterizations respectively. Barnaoui et al. used conversion factors from literature to estimate
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effective dose and found a mean value of 4.8 and 7.3 mSv for diagnostic and therapeutic proce-
dures respectively. Johnson et al. calculated effective dose from measurements performed in
anthropomorphic phantoms using TLD dosimeters. Diagnostic procedures resulted in a
median effective dose of 9.1 mSv, while therapeutic procedures yield 13.77 mSv [14]. Effective
doses determined in the current study are amongst the lowest values found in literature, as
shown in Table 6 from Ubeda et al. [21]. This table shows only lower values reported by Ubeda
et al. For patient weight <30 kg and>60 kg we see about the same median effective doses, but
for weights between 30 and 60 kg the effective dose is higher in this study. This can be attrib-
uted to a limited patient cohort in the latter weight category and a different weight distribution
since CFED values are higher in this study for patients <30 kg and smaller for patients >50 kg.
Furthermore Ubeda et al. only included patients younger than 16 years of age. Current study
did not exclude any congenital heart disease patients based on patient age, with median
(P25-P75) age equal to 4.3 (0.9–15.6) years. The youngest patient was 2 days old, the oldest one
was 69.6 years [21].
A summary of conversion factors from DAP to effective dose (CFED) are shown in Table 8,
which is an adjustment of Table 4 of Harbron et al. [13]. Effective dose conversion factors
using tissue weighting factors of ICRP publication 60 are also provided in the latter table for
comparison with literature. Conversion factors of the current study are closest to the values of
Barnaoui et al. If we would have calculated effective doses according to the latter conversion
factors, we would have overestimated and underestimated effective dose by on average 14.3%
and 14.5% for frontal and lateral exposures respectively [9]. Applying conversion factors from
Ubeda et al. to the procedures of current study would have yielded on average an underestima-
tion by 28% [21].
Median (P25-P75) lifetime risk for cancer incidence and mortality from this study is respec-
tively equal to 0.034 (0.014–0.103)% and 0.021 (0.009–0.063)%. Few studies in literature
included LAR calculations. Bacher et al. showed a median LAR for stochastic effects of 0.08%
for all patients combined. For patients younger than 1 year of age, their results show a median
LAR of 0.10%, this study reports a LAR of 0.044%. For age groups 2–5 and 6–10 years they
note a LAR of 0.08% and 0.05% respectively, according to the current study these values are
0.029% and 0.030% for the same respective age groups [6]. Johnson et al. report an overall
median LAR of cancer incidence of 0.065%, however their study only included children youn-
ger than or equal to 6 years. For the same age groups we report a LAR of 0.034%. To be able to
Table 8. CFED in literature.
CFED
[mSv.Gy-1.cm-2]
Barnaoui Schmidt Onnasch Karambatsakidou Current study Current study
ICRP103 ICRP60 ICRP60 ICRP60 ICRP103 ICRP60
Age AP/LAT AP/LAT AP+LAT AP/AP+LAT AP/LAT/AP+LAT AP/LAT/AP+LAT
0 y
(3.4 kg)
3.5/3.5 2.05/2.34 2.72 3.7/3.7 2.26/4.83/3.3 1.94/3.74/2.68
1 y
(9.2 kg)
1.6/2.6 0.82/1.16 1.01 1.9/1.9 1.35/2.52/1.71 1.22/1.98/1.46
5 y
(19 kg)
0.8/1.3 0.42/0.64 0.49 1.0/1.0 0.89/1.48/1.18 0.8/1.33/1.06
10 y
(32.4 kg)
0.5/0.8 0.24/0.38 0.29 0.6/0.7 0.46/0.79/0.59 0.45/0.66/0.53
15 y
(56.3 kg)
0.3/0.4 0.13/0.22 0.16 0.4/0.4 0.33/0.5/0.42 0.32/0.4/0.36
Comparison to literature, adjusted from Harbron et al.
https://doi.org/10.1371/journal.pone.0220359.t008
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compare with LAR values from literature, the LAR values from current study are reported
only in this paragraph for a DDREF of 1.5.
The use of ED and LAR has some inherent limitations. ED was not intended to assess sto-
chastic risk and should not be used for individual risk assessment. The ED calculated in cur-
rent study can for example be used to compare similar procedures in other centres working
with either similar or different technologies, as also suggested by ICRP103. Appropriate use of
effective dose is discussed in detail by Fisher et al [16, 22]. The BEIR committee states that due
to limitations in the data used to develop their risk models for low levels of low-LET ionizing
radiation, risk estimates are uncertain, and estimates that are a factor of two or three larger or
smaller cannot be excluded [5]. Additionally, when calculating individual risk, we are not
assessing risk to one actual individual, we are assessing the probability of a biological effect
(e.g. cancer incidence or mortality) in a theoretical population with the same characteristics as
the actual patient (e.g. age and sex) and that one theoretical individual in the latter population
might exhibit this biological effect [23]. Communicating risk to an individual patient should
therefore be discouraged since the actual risk for one specific patient might deviate signifi-
cantly from the calculated LAR. The latter parameter can be more meaningful on a patient
population level, where it can for example be used to compare different technologies for simi-
lar procedures [24, 25]. The only parameter obtained through the Monte Carlo calculations
that could be communicated to one specific patient is organ dose. However we should note
that an actual patient is still different from the age and size adjustable hermaphrodite mathe-
matical phantoms as implemented in PCXMC.
Automated risk assessment
Brambilla et al. was also able to calculate organ and effective doses in coronary angiography
and PCI procedures, taking into account each fluoroscopy and cinegraphy exposure per proce-
dure. However, their simulations were only performed on an adult mathematical phantom,
including 2 isocenter positions, one for male and one for female. This study adjusts the mathe-
matical phantom dimensions and isocenter positions according to the patients age and size,
for each irradiation event, yielding a more accurate resemblance to reality [26].
Using in-house developed scripts, the Monte Carlo simulation results are stored together
with the exposure parameters of the RDSR into one database. Integrating this workflow into
dose management software, could expand their scope to organ dose and risk management.
Making risk information centrally available for users, could help selecting the optimal medical
imaging exam and device when multiple options are available and could improve risk commu-
nication towards the patient, the general public and other physicians. Future epidemiology
research can benefit from the availability of patient-specific organ doses in dose management
systems, as implemented in current study.
Conclusion
The average and median values of DAPBW and DAPBWxFT analyzed in this study are well
matching the values found in literature. DAPBWxFT is the recommended primary DRL param-
eter, since linear regression between DAP and BWxFT showed the best correlation combined
with a narrower 95% confidence interval. When sufficient data are available, DRLs should be
calculated for separate procedure types. However, pooling procedures into one single group,
still yields appropriate DRL values for DAPBWxFT, which is recommended in smaller depart-
ments with less data.
When Monte Carlo simulations are not an option, DAPBW can serve as an excellent indica-
tor of organ and effective doses. We recommend to use different conversion factors for
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different body weight groups when Monte Carlo simulations are no option. Furthermore,
using different conversion factors for frontal and lateral projections would further improve
accuracy of organ and effective doses. However, conversion factors in literature should be cho-
sen with much care, trying to match exposure parameters and patient size parameters as much
as possible to your own practice and patient population.
Supporting information
S1 Dataset. An anonymous dataset containing the exposure information of any irradiation
event available in the RDSRs of all included procedures.
(XLSX)
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